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Edited by Veli-Pekka LehtoAbstract Adiponectin is thought to play a decisive role in the
relationships among obesity, insulin resistance and cardiovascu-
lar risk. This study investigated whether cardiomyocytes synthe-
size and secrete adiponectin, and the eﬀects of this hormone on
cardiac cells. RT-PCR showed that mouse, rat and human
cardiomyocytes produced mRNA for adiponectin and adiponec-
tin receptors 1 and 2. Immunohistochemistry conﬁrmed the pres-
ence of adiponectin in the cytoplasm of cultured cardiomyocytes,
and radioimmunoassay showed that these cells secreted adipo-
nectin into the culture medium. Exogenous adiponectin enhanced
glucose and fatty acid uptake and induced AMPK phosphoryla-
tion in cultured cardiomyocytes. Our results demonstrate that
adiponectin is synthesized and secreted by isolated murine and
human cardiomyocytes, and suggest that the local production
of this hormone by cardiomyocytes could be involved in the
regulation of cardiac metabolism and function.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Recent intensive research on obesity has shown that adipo-
kines mediate many of its cardiovascular and metabolic com-
plications, although the pathogenic relationships among
obesity, metabolic syndrome, and cardiovascular complica-
tions remain poorly understood. Adiponectin is an approxi-
mately 30-kDa protein that is secreted by adipose tissue,
circulates in plasma as multimeric complexes at relatively high
concentration (2–10 lg/ml), and plays a crucial role in the
association among obesity, type II diabetes, and insulin resis-
tance [1]. In humans, adiponectin is reduced in the serum of
type II diabetic and obese patients, and is further decreased
in patients with cardiovascular disease, being increasingly
recognized as both a potential biomarker for the metabolic*Corresponding author. Laboratorio de Investigacio´n 1, Planta Baja,
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Santiago de Compostela, Travesı´a Choupana s/n, 15706 Santiago de
Compostela, Spain. Fax: +34 981 951068.
E-mail address: frlago@usc.es (F. Lago).
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.07.098syndrome and cardiovascular disease, and a possible therapeu-
tic target [2]. Adiponectin has been reported to have antiather-
ogenic and antiinﬂammatory eﬀects [3], to enhance endothelial
vasodilation [4], and to play a role in myocardial remodelling
after ischaemic injury [5]. On the other hand, plasma adiponec-
tin levels correlate negatively with C-reactive protein levels [6],
high plasma adiponectin concentrations are associated with
lower risk of myocardial infarct in men [7], and hypoadiponec-
tinaemia is a risk factor for hypertension [8]. Recently, an
adiponectin gene mutation has been associated with coronary
artery disease as well as with metabolic syndrome [9].
While adiponectin receptors (Adipo-R1 and Adipo-R2) are
present in most organs [10], adiponectin itself has generally
been written of as it were produced exclusively by adipocytes.
However, adiponectin synthesis has recently been observed in
other tissues [11–14], where it may have autocrine and/or para-
crine functions. In view of this, and given the cardiovascular ef-
fects of adiponectin noted above, we wondered whether
cardiomyocytes synthesize and secrete this hormone. In this
study we found that cardiomyocytes can synthesize and secrete
adiponectin and that exogenous adiponectin increases their
uptake of glucose and free fatty acids and leads to phosphory-
lation of AMPK. The present ﬁndings demonstrate that adipo-
nectin is not adipocyte speciﬁc but local production of
adiponectin by cardiomyocytes might have important functions
in the regulation of the cardiac function and/or metabolism.2. Material and methods
All sera and media were from Life Technologies Ltd. (Poole, UK),
and all other products from Sigma Chemical Co. (St. Louis, MO,
USA), unless otherwise stated.2.1. Cells
HL-1 cells, a line of adult mouse atrial cardiomyocytes, were a
generous gift of Dr. W.C. Claycomb of Louisiana State University
Medical Center (New Orleans, LA, USA) and primary cultures of
human (with cells obtained from fragments of right atrial appendage,
previous informed consent obtained from the patients) and neonatal
rat cardiomyocytes were cultured as previously described [15].2.2. Glucose uptake experiments
10 lg/ml full-length recombinant adiponectin (BioCat GmbH, Hei-
delberg, Germany) [16] was used for the treatments. Glucose uptake
was determined as described previously [17]. In some experiments, anblished by Elsevier B.V. All rights reserved.
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(araA) (MP Biomedicals, LLC, Eschwege, Germany) was added
20 min before the addition of adiponectin, as previously described [18].
2.3. BODIPY-labeled fatty acid uptake
HL-1 cells (4 · 105) were serum starved for 12 h and then treated
for 0.5, 2, 6 and 12 h with 10 lg/ml adiponectin, and incubated
30 s with PBS containing 10 lM 4,4-diﬂuoro-5-methyl-4-bora-3a,4a-
diaza-s-indacene-3-dodecanoic acid (BODIPY 500/510 C1, C12;
Molecular Probes, Inc., Eugene, OR, USA), and 20 lM fatty acid-
free BSA. Cells were also stained with propidium iodide (1 lM) to
determine dead cells and analyzed by ﬂow cytometry in a FAC-
SCALIBUR (Becton & Dickinson, San Jose´, CA, USA) using the
program Cell Quest.
2.4. Western blots
HL-1 cells (5 · 105) were starved 12 h and treated for 5, 30, or
120 min with 10 lg/ml adiponectin. Lysates were analyzed by Western
blot using either rabbit anti-phospho-AMPK antibody (Cell Signalling
Technology, Inc., Beverly, MA, USA) or rabbit anti-AMPK antibody
(Cell Signalling Technology, Inc.).
2.5. Immunohistochemistry
Slide-borne cells were ﬁxed in 96% ethanol for 10 min. Antigen re-
trieval was only done for the adiponectin localization: cells were pre-
treated for 40 min in 0.1 M sodium citrate buﬀer (pH 6) in a water
bath at 95–99 C. Immunohistochemical procedure:
1. Primary antibody. Goat anti-adiponectin antibody (ACRP-30 N-
20, Santa Cruz Biotechnology, Santa Cruz, CA, USA), at a dilution
of 1/200, overnight at 4 C; rabbit anti-Adipo-R1 antibody (41–65)
(Phoenix Pharmaceuticals, Belmont, CA, USA) 1/100 for 1 h at
room temperature (RT) or rabbit anti-Adipo-R2 antibody (4–39)
(Phoenix Pharmaceuticals) 1/50 overnight at RT.
2. 3% Hydrogen peroxide (Merck, Darmstadt, Germany) 10 min.
3. Detection system.
 LSAB System HRP (Dakocytomation, Carpinteria, CA,
USA) (multilink biotinylated anti-mouse, rabbit and goat
IgG, 30 min, and streptavidin-conjugated horseradish peroxi-
dase, 30 min), for the adiponectin detection, and
 Envision HRP anti-rabbit and mouse (Dakocytomation) for
30 min, in the case of the adiponectin receptors
4. 3,3 0-Diaminobenzidine tetrahydrochloride (Dakocytomation) for
10 min.
Between steps, sections were washed twice for 5 min with TBS (0.05
M Tris buﬀer of pH 7.6 containing 0.3 MNaCl), and before step 6 with
distilled water. Counterstaining was done with Harris haematoxylin
for 1 min.Table 1
Primers used for RT-PCR
Protein Primer sequences
Mouse Adiponectin [19] 5 0-GACGTTACTACAACTGAAGAGC-3
5 0-CATTCTTTTCCTGATACTGGTC-3
Mouse Adipo-R1 [10] 5 0-ACGTTGGAGAGTCATCCCGTAT-3
5 0-CTCTGTGTGGATGCGGAAGAT-30
Mouse Adipo-R2 [10] 5 0-TCCCAGGAAGATGAAGGGTTTAT
5 0-TTCCATTCGTTCGATAGCATGA-3
Human Adiponectin [20] 5 0-TGGTGAGAAGGGTGAGAA-30
5 0-AGATCTTGGTAAAGCGAATG-3 0
Human Adipo-R1 [10] 5 0-TTCTTCCTCATGGCTGTGATGT-3
5 0-AAGAAGCGCTCAGGAATTCG-3 0
Human Adipo-R2 [10] 5 0-ATAGGGCAGATAGGCTGGTTGA-3
5 0-GGATCCGGGCAGCATACA-30
Rat Adiponectin [21] 5 0-ACCCAGGAGATGCTG-30
5 0-ACCTGGAGCCAGACTTGGTC-3 0
Rat Adipo-R1 [16] 5 0-CTTCTACTGCTCCCCACAGC-3 0
5 0-TCCCAGGAACACTCCTGCTC-3 0
Rat Adipo-R2 [16] 5 0-CCACACAACACAAGAATCCG-3 0
5 0-CCCTTCTTCTTGGGAGAATGG-30Double immunoﬂuorescence. Mouse monoclonal antibodies to car-
diac myosin heavy chain (MHC, Abcam, Cambridge, UK, clone 3-
48) and the same antibodies to adiponectin, Adipo-R1 or Adipo-R2
as above were used. Antigen retrieval using the water bath was only
done for double immunoﬂuorescence of adiponectin and MHC. Cells
were incubated in:
1. Anti-adiponectin antibody, anti-Adipo-R1 antibody or with anti-
Adipo-R2 antibody;
2. 1/200 Alexa Fluor 488 F(ab 0)2 fragment of rabbit anti-goat IgG
(Molecular Probes, Eugene, OR, USA) for adiponectin detection,
1 h at RT or 1/200 Alexa Fluor 488 F(ab 0)2 fragment of goat
anti-rabbit IgG (Molecular Probes) for adiponectin receptors detec-
tion, 1 h at RT;
3. 1/1000 mouse anti-(cardiac myosin heavy chain) antibody (Abcam;
Cambridge, UK); for 1 h at RT and
4. 1/100 Cy3-conjugated F(ab 0)2 fragment of sheep anti-mouse IgG
(Sigma, St. Louis, MO, USA) for 1 h.
Controls. As positive control tissues, mouse and rat adipose tissue
was used for adiponectin, mouse and rat striated muscle for Adipo-
R1, and mouse and rat liver for Adipo-R2. Negative controls included
preadsorption of the anti-adiponectin antibody with 10 nmol/ml hu-
man or mouse adiponectin (BioCat), or with blocking peptide (sc-
17044, Santa Cruz).
2.6. RT-PCR
1–2 lg of total RNA was back-transcribed and the resulting cDNA
was used as a PCR template in a reaction mixture containing the prim-
ers for mouse, human and rat adiponectin and adiponectin receptors
[10,16,19–21] listed in Table 1.
2.7. Sequence analysis
Human and mouse adiponectin, and mouse Adipo-R1 and Adipo-
R2 PCR products were sequenced using a BIGDye Terminator kit
(Amersham Biosciences) and an ABI Prism automated DNA sequen-
cer (Applied Biosystems, Foster City, CA, USA).
2.8. Adiponectin radioimmunoassay
Adiponectin levels in the media in which cultured HL-1 and human
cardiomyocytes had been starved for 24 h were determined using a kit
from Linco Research, Inc. (St. Charles, MO, USA).
2.9. Statistical analysis
Results shown are the means ± S.E.M. of at least three independent
experiments. The signiﬁcance of diﬀerences was estimated by ANOVA
followed by Student–Newmann–Keuls multiple comparison tests;
P < 0.05 was considered signiﬁcant.Annealing (C) Product size (bp)
0 56 532
0
0 60 132
-3 0 60 72
0
56 221
0 62 70
0 62 75
55 405
60 138
60 117
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3.1. Expression of adiponectin and adiponectin receptor genes
RT-PCR for adiponectin in HL-1 cardiomyocytes aﬀorded a
cDNA band of the same size as that ampliﬁed from mouse
white adipose tissue (WAT) (Fig. 1, panel A.1). HL-1 cells also
expressed both Adipo-R1 and Adipo-R2 genes at levels similar
to those observed in whole mouse myocardium and mouse li-
ver, respectively (Fig. 1, panel B.1). The identities of the adipo-
nectin, Adipo-R1 and Adipo-R2 gene PCR products were
conﬁrmed by sequencing (data not shown).
RT-PCR also ampliﬁed cDNA for adiponectin from RNAs
obtained from primary cultured (PC) human atrial cardiomyo-
cytes, myocardium and fat (Fig. 1, panel A.2), cDNAs for Adi-
po-R1 from cultured human atrial cardiomyocytes and human
skeletal muscle (Fig. 1, panel B.2), and cDNAs for Adipo-R2
from cultured human atrial cardiomyocytes and human liver
(Fig. 1, panel B.2).
Similarly, RT-PCR ampliﬁed adiponectin cDNA from RNA
obtained from adult rat myocardium (data not shown). Adipo-
R1 mRNA was present in the hearts of 1-day-old rats, but
Adipo-R2 was not (Fig. 1, panel B.3). Adipo-R2 mRNA alsoFig. 1. RT-PCR results showing expression of genes for adiponectin, Adipo-R
HL-1 cardiomyocytes and white adipose tissue. Panel A.2: adiponectin cD
human myocardium and human fat. Panel B.1: Adipo-R1 cDNA ampliﬁed f
R2 cDNA ampliﬁed from HL-1 cardiomyocytes and mouse liver. Panel B.2
culture (PC) and human skeletal muscle, and Adipo-R2 cDNA ampliﬁed fr
Panel B.3: Adipo-R1 cDNA ampliﬁcation from primary cultures of 1-day-o
cDNA from primary cultures of 1-day-old rat cardiomyocytes (CM 1) and ra
and livers of 6-day-old, 9-day-old, and 25-day-old male rats. Panel B.4 (lowappeared to be absent from the hearts of 6-day-old and 9-day-
old rats, but was clearly present in those of 25-day-old rats
(Fig. 1, panel B.4).
That reverse transcription had proceeded properly was con-
ﬁrmed in all cases by ampliﬁcation of GAPDH. The number of
PCR cycles was in all cases 35.
3.2. Synthesis of adiponectin and adiponectin receptors by
cardiomyocytes
The cytoplasm of HL-1 cells showed intense immunoreactiv-
ity with anti-adiponectin, anti-Adipo-R1 and anti-Adipo-R2
antibodies (Fig. 2A, F and G, respectively). Preadsorption of
the primary anti-adiponectin antibody with 10 nmol/ml of
mouse adiponectin did not show any positive reaction
(Fig. 2B). Rat and mouse myocardial tissue also stained posi-
tive for adiponectin (Fig. 2E shows this for rat). As positive
controls, rat striated muscle and liver showed intense immuno-
staining for adiponectin receptors 1 and 2, respectively
(Fig. 2H and I). The cytoplasm of human cardiomyocytes in
primary culture also showed intense immunoreactivity with
anti-adiponectin antibody (Fig. 2C). Preadsorption of the pri-
mary anti-adiponectin antibody with 10 nmol/ml of human1 and Adipo-R2. Panel A.1: adiponectin cDNA ampliﬁed from mouse
NA ampliﬁed from human cardiomyocytes in primary culture (PC),
rom HL-1 cardiomyocytes and whole mouse myocardium, and Adipo-
: Adipo-R1 cDNA ampliﬁed from human cardiomyocytes in primary
om human cardiomyocytes in primary culture (PC) and human liver.
ld rat cardiomyocytes (CM 1) and rat skeletal muscle, and Adipo-R2
t liver. Panel B.4 (upper): Adipo-R2 cDNA ampliﬁcation from hearts
er): as for the upper panel, but with female rats.
Fig. 2. Immunohistochemical detection of adiponectin, Adipo-R1 and Adipo-R2 in cardiomyocytes and myocardium (objective magniﬁcation 40· as
otherwise stated). (A) Adiponectin immunostaining was mainly localized in the cytoplasm of HL-1 cells. (B) Preadsorption control with mouse
recombinant adiponectin (10 nmol/ml) shows no positive immunostaining. (C) Adiponectin immunostaining was also evident in the cytoplasm of
human atrial myocardium cells. Positive reaction was mainly localized in the cytoplasm in the vicinity of the nuclei. (D) Preadsorption control with
human recombinant adiponectin (10 nmol/ml) resulted in a negative reaction. (E) Rat left ventricle, showingmyocardium positively immunostained for
adiponectin (objective magniﬁcation 10·). (F–G) HL-1 cells with cytoplasm showing diﬀuse immunopositivity for Adipo-R1 (F) and Adipo-R2 (G).
(H) Rat striated muscle: myocytes, but not connective tissue cells, are positively immunostained for Adipo-R1. (I) Rat liver, positively immunostained
for Adipo-R2. (J–L) Photomicrographs of human atrial myocardium cells in primary culture showing immunoﬂuorescence of adiponectin (J), cardiac
myosin heavy chain (K), and both these targets (L). (M–O) Photomicrographs of human atrial myocardium cells in primary culture showing
immunoﬂuorescence of Adipo-R1 (M), cardiac myosin heavy chain (N), and both these targets (O). (P–R) Photomicrographs of human atrial
myocardium cells in primary culture showing immunoﬂuorescence of Adipo-R2 (P), cardiac myosin heavy chain (Q), and both these targets (R).
5166 R. Pin˜eiro et al. / FEBS Letters 579 (2005) 5163–5169adiponectin did not show any positive reaction (Fig. 2D). The
possibility that the human cells were ﬁbroblasts rather than
cardiac muscle ﬁbres was ruled out in colocalization studiesshowing positivity for adiponectin, Adipo-R1, and Adipo-
R2, by their immunoreactivity with antibody against cardiac
myosin heavy chain (Fig. 2J–R).
R. Pin˜eiro et al. / FEBS Letters 579 (2005) 5163–5169 51673.3. Secretion of adiponectin by cultured HL-1 cells and primary
cultures of human cardiomyocytes
The adiponectin concentrations measured by RIA in the
media in which starving HL-1 cells and human cardiomyocytes
were cultured were 2.7 ± 0.6 ng/ml (n = 5) and 3.1 ± 0.2 ng/ml
(n = 10), respectively.
3.4. Adiponectin-induced increases in glucose and fatty acid
uptake by cardiomyocytes
Treatment with a physiological concentration of adiponectin
(10 lg/ml) increased 2-deoxy-D-[3H] glucose uptake by HL-1
cardiomyocytes by 4.5 ± 1.6% at 5 min (not signiﬁcant,
n = 4), by 12.9 ± 2.6 at 30 min (P < 0.01, n = 4), and by
18.5 ± 2.8% at 120 min (P < 0.01, n = 4), whereas treatment
with 300 nM insulin for 20 min increased 2-deoxy-D-[3H] glu-
cose uptake by 47.5 ± 7.6% (P < 0.001, n = 4) (Fig. 3, panel A).
2-Deoxy-D-[3H] glucose uptake by neonatal rat cardiomyo-
cytes was increased by 49.6 ± 10.4% by treatment for 24 h with
10 lg/ml adiponectin (P < 0.05 vs. control, n = 4), by
90.1 ± 19.9% by stimulation with 100 nM insulin for 60 min
(P < 0.01 vs. control, n = 4), and by 138.2 ± 20.2% by co-stim-
ulation with insulin and adiponectin (P < 0.001 vs. control,
n = 4) (Fig. 3, panel B.1). In HL-1 cells, 2-deoxy-D-[3H] glucose50
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Fig. 3. Uptake of 2-deoxy-D-glucose by cardiomyocytes. Panel A: time course
insulin of HL-1 cardiomyocytes (n = 4). Panel B: primary cultures of neonatal
following 24 h treatment with 10 lg/ml adiponectin, 60 min treatment with
Statistical signiﬁcance: *P < 0.05; **P < 0.01; ***P < 0.001.uptake was enhanced by 27.02 ± 5.5% by 24 h adiponectin
(P < 0.05 vs. control, n = 8), by 48.7 ± 10.4% by insulin
(P < 0.001 vs. control, n = 8), and by 70.5 ± 10.6% by adiponec-
tin plus insulin (P < 0.001 vs. control, n = 8) (Fig. 3, panel B.2).
Thus adiponectin both increased basal glucose uptake and en-
hanced insulin-stimulated glucose uptake by cardiomyocytes.
Furthermore, adiponectin treatment also increased fatty
acid uptake by HL-1 cardiomyocytes in a time dependent man-
ner (Fig. 4), with the highest eﬀect observed at 30 min after
treatment (units as BODIPY ﬂuorescence means)(975.2 ± 37.1
vs. 779.8 ± 23.5 of control, P < 0.01, n = 5). With treatments of
6 h the eﬀect was still evident but it started to decrease
(785.2 ± 16.4 vs. 737.6 ± 4.3 of control, P < 0.05, n = 3), and
it disappeared with treatments of 12 h (767.7 ± 39.5 vs.
745.4 ± 11.3 of control, not signiﬁcant, n = 3).
3.5. Adiponectin-induced phosphorylation of AMP-activated
protein kinase (AMPK) in HL-1 cardiomyocytes
Phosphorylation of AMPK in HL-1 cells was increased
by 72.0 ± 17.3% by 5 min treatment with 10 lg/ml adipo-
nectin (P < 0.05, n = 4), by 53.0 ± 6.3% by 30 min treat-
ment (P < 0.05, n = 4), and by 117.0 ± 11.0% by 120 min
treatment (P < 0.001, n = 4) (Fig. 5). Noteworthy, the2-
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Fig. 5. Panel A: Western blots of HL-1 cell lysates following staining
with anti-phospho-AMPK antibody (a-pAMPK) or anti-AMPK
antibody (a-AMPK); times indicate the duration of adiponectin
treatment. Panel B: Amount of phospho-AMPK, relative to controls,
in four independently performed experiments (*P < 0.05; ***P <
0.001).
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Fig. 4. Statistical analysis (of at least three independent experiments)
of free fatty acid uptake by HL-1 cardiomyocytes after 10 lg/ml
adiponectin treatment. *P < 0.05; **P < 0.01.
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cardiomyocytes was diminished in a 72.1 ± 5.3% (P < 0.01,
n = 3) by the addition of the AMPK speciﬁc inhibitor araA
20 min before the treatment with adiponectin.4. Discussion
Until recently it appeared to have been generally accepted
that adiponectin was only synthesized by adipocytes [3].However, recent studies have found that mouse liver cells
can synthesize adiponectin under appropriate conditions [12];
that adiponectin gene expression can be induced in human
myotubes by exposure to an adiponectin-containing HEK293
cell culture supernatant [11]; that adiponectin synthesis can
be induced both in myotubes and in muscle in response to pro-
inﬂammatory cytokines [13]; and that adiponectin is expressed
in bone-forming cells [14]. Nevertheless, despite these discover-
ies and the intensive research on the cardiovascular eﬀects of
adiponectin, hitherto no studies have been published that
have investigated the possibility that cardiac cells synthesize
adiponectin.
Our results in this study show in the ﬁrst place that adipo-
nectin can be synthesized and secreted by cardiomyocytes of
both human and murine origin. As far as we know, this is
the ﬁrst report of adiponectin synthesis and secretion by
cardiomyocytes. It may be pointed out that although the
adiponectin content of cardiomyocytes seems to be less than
that of adipose tissue, this diﬀerence does not suﬃce to throw
doubts on the eﬃcacy of adiponectin secretion by cardiomyo-
cytes, since cardiomyocyte-secreted adiponectin may well
mediate paracrine and/or autocrine signalling pathways rather
than long-range mechanisms.
We also found that, as expected, HL-1 cells (a cultured line
derived from murine atrial cardiomyocytes that maintains a
heart-speciﬁc phenotype and is accordingly used as an
in vitro model in studies of cardiomyocyte biology [15]) and
cultured human cardiomyocytes express genes for the adipo-
nectin receptors Adipo-R1 and Adipo-R2. Interestingly,
1-day-old rat hearts contained Adipo-R1 mRNA but not Adi-
po-R2 mRNA, which only appeared at some time between the
ages of 9 and 25 days. The late appearance of Adipo-R2 may
perhaps be related to the sweeping postnatal changes in the
intermediate metabolism of the heart, which switches from lac-
tate and glucose to fatty acids as its main sources of energy
[22]. Although additional work in this subject is necessary to
elucidate the physiological relevance of this ﬁnding, this may
be a physiological mechanism allowing adaptation of cardiac
responsiveness to diﬀerent physiological and pathological
settings.
Although the processes initiated by the binding of adipo-
nectin to its receptors on cardiomyocytes may be manifold,
two at least were identiﬁed in this study, in which adiponectin
signiﬁcantly enhanced glucose and fatty acid uptake by
cardiomyocytes. These ﬁndings are in keeping with recent re-
ports of similar adiponectin eﬀects on glucose uptake by
C2C12 myocytes [23] and adipocytes themselves [18].
We also found that adiponectin treatment induced AMPK
phosphorylation in HL-1 cardiomyocytes. It seems possible
that, as in other cell types [23], the adiponectin-promoted
enhancement of glucose uptake by cardiomyocytes may be
mediated by activation of AMPK, especially since AMPK is
known to mediate glucose uptake and GLUT4 translocation
in heart muscle [24]. In fact, we have observed that, in HL-1
cardiomyocytes, the AMPK speciﬁc inhibitor araA blunted
the adiponectin-induced increase on glucose uptake, as it does
in adipocytes [18]. Recently, it has been reported that adiponec-
tin inhibits hypertrophic signaling in the myocardium through
activation of AMPK [25], further supporting the relevance of
adiponectin signaling on cardiomyocyte function.
In conclusion, the main results of this study are that (a)
adiponectin can be synthesized and secreted by human and
R. Pin˜eiro et al. / FEBS Letters 579 (2005) 5163–5169 5169murine cardiomyocytes in culture, and (b) adiponectin can di-
rectly regulate cardiomyocyte metabolism through AMPK
activation.
The observed expression and secretion of adiponectin by
cardiomyocytes add more complexity to the largely unknown
regulation of cardiomyocyte metabolism/function by adipo-
kines. It may be hypothesized that both fat-derived and local
cardiac-derived adiponectin could be essential for cardiomyo-
cyte metabolism and functionality, and that the failure of
one or both of these mechanisms might be determinant in
the development of several cardiac pathologies.Acknowledgments: Francisca Lago and Oreste Gualillo are researchers
funded by Spanish Ministry of Health under Health Research Fund
(FIS) contracts 99/3040 and 00/3051.References
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